NCT00333528View on ClinicalTrials.gov

A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 1, 2007

Primary Completion Date

April 1, 2008

Study Completion Date

August 1, 2008

Conditions
Healthy Volunteers
Interventions
DRUG

Human butyrylcholinesterase (HuBChE) derived from human plasma

Intramuscular administration

DRUG

Placebo: Normal saline

Intramuscular administration

Trial Locations (1)

66219

Quintiles Phase 1 Services, Lenexa

All Listed Sponsors
collaborator

DynPort Vaccine Company LLC, A GDIT Company

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY

NCT00333528 - A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly | Biotech Hunter | Biotech Hunter